WuXi AppTec’s leadership played down concerns about reduced demand for glucagon-like peptide-1 receptor agonist (GLP-1RA) manufacturing after leading obesity player Eli Lilly released lower-than ...

Legislation would have cut Chinese businesses off from US WuXi executives say the companies continue to sign new clients WuXi AppTec Co. and WuXi Biologics Cayman Inc. said they see a brighter 2025 ...

WuXi AppTec Co. and WuXi Biologics Cayman Inc. said they see a brighter 2025 for the Chinese biotech and drug companies after the US Biosecure legislation that threatened to cut them out from ...

WuXi AppTec’s leadership played down concerns about reduced demand for glucagon-like peptide-1 receptor agonist (GLP-1RA) manufacturing after leading obesity player Eli Lilly released ...

At the recent JP Morgan Healthcare Conference 2025, WuXi Biologics’ CEO Chris Chen said the company continues to sign foreign clients and investing in the US, despite political headwinds related to ...

(Yicai) Jan. 14 -- WuXi AppTec’s shares rose after the pharmaceutical services provider sold stakes in an affiliated company, pocketing HKD2.4 billion (USD312 million) after transaction costs. It is ...

SHANGHAI, Jan. 12, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences ...

WuXi Biologics differentiates itself from other well-established global contract development and manufacturing organizations, with its "follow-and-win the molecule" and "global dual-sourcing ...